-+ 0.00%
-+ 0.00%
-+ 0.00%

Palatin Technologies Presents New Preclinical Data Highlighting Its Proprietary MC4R-Selective Peptide Agonist Programs At ObesityWeek 2026

Benzinga·11/16/2026 12:33:50
Listen to the news
  • Novel peptide and long-acting lipidated peptide agonists demonstrate potent MC4R activity with minimal to no MC1R activity, supporting the potential to substantially reduce or eliminate hyperpigmentation
     
  • Significant reductions in body weight and food intake demonstrated in preclinical models, with encouraging preliminary cardiovascular finding
     
  • Proprietary lipidation technology supports once-weekly or potentially less frequent dosing; lead candidate PL2001 advancing toward first-in-human studies in the first half of 2027

PRINCETON, N.J., Nov. 16, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NASDAQ:PTN), a biopharmaceutical company developing differentiated, next-generation melanocortin receptor agonists, today announced the presentation of new preclinical data highlighting the Company's proprietary MC4R-selective peptide agonist programs at ObesityWeek® 2026, being held November 14–17 in Washington, D.C.